Sage Journals: Discover world-class research

Abstract

Objective

To investigate the association between polymorphisms of the interleukin 10 (IL10) gene and risk of gastric cancer (GC) and atrophic gastritis (AG).

Methods

This study enrolled patients with GC, patients with AG and healthy control subjects. Demographic data were collected and the IL10 gene –1082A/G, –819C/T and –592A/C polymorphisms were genotyped. An enzyme-linked immunosorbent assay was performed to detect Helicobacter pylori infection.

Results

The study enrolled 556 participants including 208 in the GC group, 116 in the AG group and 232 controls (CON group). In a recessive model of the IL10–819C/T polymorphism, a significantly decreased risk of GC was found compared with AG and non-cancer subjects, respectively (AG→GC: odds ratio OR 0.41; non-cancer→GC: OR 0.57). The CC genotype demonstrated a significantly increased risk of AG compared with CON. Similar significant results were detected in males and H. pylori-negative subgroups. The ACC haplotype was associated with a decreased risk of GC compared with AG. The ATC haplotype was associated with a decreased risk of AG compared with the CON group, but it was associated with an increased risk of GC compared with AG.

Conclusion

The IL10 gene promoter –819C/T (rs1800871) polymorphism was associated with the risk of GC and AG in a Chinese population.

Keywords

polymorphism gastric cancer

Introduction

Gastric cancer (GC), one of the most common cancers of the digestive tract worldwide, is the second leading cause of cancer-related deaths.¹ As a complex and multistep process, GC is initiated by both genetic and environmental factors with their complicated interactions.² Although environmental factors including Helicobacter pylori infection have been identified as risk factors for GC, genetic influences and their interactions with environmental factors also play an important role in gastric carcinogenesis.³ Gene polymorphisms are the basis of the diversity of individual genetic susceptibility, of which single nucleotide polymorphisms (SNPs) are the most common form of genetic variation. Therefore, investigation and identification of the SNPs associated with susceptibility to GC and its precancerous diseases are critical to unrabel the disease aetiology and identify promising biomarkers and therapeutic targets for GC.⁴

Inflammatory and immune reactions have been suggested to be implicated in the occurrence and progression of various types of cancers including GC.⁵ Cytokines are secretory proteins that are involved in the regulation of various biological activities including haematopoiesis, inflammation and immunity.⁶ Interleukin (IL)-10 is a cytokine with multiple biological effects covering anti-inflammation and antiallergy.⁷ Also, IL-10 is an immunosuppressive cytokine involved in the initiation and progression of cancer.⁸ It has been reported that the over-expression of IL-10 suppressed the phagocytosis of macrophage effect of cells, thus contributing to the spread of cancer cells.⁹ In a study in which the mouse IL10 gene was transfected into human melanoma cells, IL-10 inhibited cancer cell growth as well as decreasing metastasis and antiangiogenesis.¹⁰

Gastric cancer progresses stepwise from normal stomach tissue through inflammatory and precancerous conditions ultimately to cancer, as described by Correa’s cascade.¹¹ Helicobacter pylori infection is the most critical risk factor for the development of GC.¹² However, the outcome of H. pylori carriers differ among different individuals, indicating that host genetic factors are also implicated in the determination of clinical outcome.¹³ The interaction between host genetic factors and H. pylori infection is the focus of considerable research. Polymorphisms of several genes including COX-2, IL-8, IL-1B and PGC have been reported to demonstrate interactions with H. pylori.^14–18 As an inflammation-related cytokine, IL10 gene polymorphisms might be involved in gastric carcinogenesis and interact with H. pylori.

In this study, three polymorphisms (–1082A/G, –819C/T, –592A/C) of the IL10 gene promoter region were investigated for their role in the susceptibility of GC. Their interactions with H. pylori were also studied to elucidate the relationship between IL10 gene polymorphisms and this environmental factor. In addition, haplotype analysis was conducted to reveal the synergistic effect of these polymorphisms.

Patients and methods

Study population

This study enrolled patients with gastric cancer (GC group), patients with atrophic gastritis (AG group) and healthy control subjects (CON group) from The First Hospital of China Medical University, Shenyang, China and the Zhuanghe Gastric Diseases Screening Programme¹⁹ between March 2002 and December 2011. All the patients had undergone a surgical operation or gastroscopic examinations and were diagnosed according to the updated Sydney gastritis classification^20,21 and the World Health Organization classification of tumours of the digestive system.²² There were two exclusion criteria for GC patients: (i) having a history of another malignant neoplasm; (ii) accepting preoperative chemotherapy or radiotherapy. The control subjects were recruited from the Zhuanghe Gastric Diseases Screening Programme and were diagnosed with a normal stomach or only superficial gastritis on the basis of gastroscopic and histopathological examinations. Other information such as sex and age of the enrolled participants was extracted from registered documents.

The study was approved by the Human Ethics Committee of The First Hospital of China Medical University, Shenyang, China. Each participant involved in the study provided written informed consent.

Genotyping of IL10 gene –1082A/G, –819C/T and –592A/C polymorphisms

A 5-ml sample of whole blood was collected from each study participant to isolate DNA. The blood samples were allowed to clot for 30 min to 1 h at room temperature and then centrifuged at 3500 g using a benchtop multi-function cryopreservation centrifuge GS-15R (Beckman Coulter Life Sciences, Indianapolis, IN, USA) at 20–25°C for 5 min. The clot was transferred to a 2 ml centrifuge tube, stored immediately at –20°C, and then moved into a freezer at −80°C until DNA extraction. IL10 gene –1082A/G, –819C/T and –592A/C polymorphisms were genotyped using polymerase chain reaction (PCR)–restriction fragment length polymorphism technology. The primer sequences were taken from previously published work.^23–26 The primers were as follows: IL10 gene –1082A/G (rs1800896) polymorphism: forward: 5ʹ-TCT TAC CTA TCC CTA CTT CC- 3ʹ, reverse: 5ʹ-CTC GCT GCA ACC CAA CTG GC-3ʹ; IL10 gene –819C/T (rs1800871) polymorphism: forward: 5ʹ-CAC TAC TAA GGC TTC CTT GGG A-3ʹ, reverse: 5ʹ-GTG AGC AAA CTG AGG CAC GAC AT-3ʹ; IL10 gene –592A/C (rs1800872) polymorphism: forward: 5ʹ-GGT GAG CAC TAC CTG ACT AGC-3ʹ, reverse: 5ʹ-CCT AGG TCA CAG TGA CGT GGG-3ʹ. Genomic DNA was purified using a method described previously with some modifications.^27,28 The primers were purchased from TaKaRa Biotechnology (Dalian, China). The total PCR reaction volume was 25 µl containing 2.5 µl of 10 × PCR buffer, 2.0 µl of 2.5 mM dNTP mixture, 1.0 µl of each upstream and downstream primer at 10 pmol/µl, 2.5 U或0.5 µL, 1.0 µl of the template DNA (TaKaRa Biotechnology), and an appropriate amount of ddH₂O. The PCR reaction was performed by preliminary denaturation at 95°C for 2 min, followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 58°C for 45 s; and 72°C for 40 s and then 72°C for 60 s using a Biometra TGradient 96 thermal cycler (Analytik Jena, Jena, Germany). Restriction enzyme MnlI (Fermentas, Waltham, MA, USA) was used to digest 10 µl of PCR product overnight for genotyping the IL10 gene –1082A/G polymorphism, generating a 139 base pair (bp) fragment for the AA genotype, and 106 bp, 33 bp fragments for the GG genotype. Restriction enzyme Hin1II (Fermentas) was used for genotyping the IL10 gene –819C/T polymorphism, generating 232 bp and 78 bp fragments for the TT genotype, and 211 bp, 78 bp and 21 bp fragments for the CC genotype. Restriction enzyme Rsa I (Fermentas) was used for genotyping the IL10 gene –592A/C polymorphism, generating 236 bp and 176 bp fragments for the AA genotype, and a 412 bp fragment for the CC genotype. The IL10 gene –1082 and IL10 gene –592 PCR products (20 µl) were separated using 3% agarose gel by electrophoresis at 150 V for 30 min, then stained using ethidium bromide for 5 min and observed using an ABI 377 DNA Sequencer (SeqGen, Torrance, CA, USA). The IL10 gene –819 PCR products (5 µl) were separated in 10% polypropylene gel and underwent electrophoresis at 120 V for 20 min followed by 80 V for 40 min, then stained using ethidium bromide for 5 min and observed using an Gel automatic imaging system GDS800 (BIO-RAD, Hercules,CA, USA). Approximately 10% of the samples were confirmed by DNA sequencing using an ABI 377 DNA Sequencer (SeqGen, Torrance, CA, USA) in this study.

Helicobacter pylori infection status

Approximately 5 ml of venous blood was collected from each participant after an overnight fast and the serum was obtained after 10 min centrifugation at 1000 g at room temperature using a benchtop multi-function cryopreservation centrifuge GS-15R (Beckman Coulter Life Sciences). The serum was used to undertake a serology test to determine the H. pylori infection status using an enzyme-linked immunosorbent assay (ELISA) that measured H. pylori immunoglobin (Ig) G levels (H. pylori-Ig G ELISA kit; BIOHIT Healthcare, Helsinki, Finland) according to the manufacturer’s instructions as described previously.²⁹ A numerical reading more than 34 enzyme immune units was regarded as a H. pylori infection positive result.

Statistical analyses

All statistical analyses were performed using the SPSS® statistical package, version 16.0 (SPSS Inc., Chicago, IL, USA) for Windows®. The differences in age between the different groups were assessed using analysis of variance. The χ²-test was used to investigate differences between categorical variables including sex and H. pylori infection status. The association between each SNP and the risk of AG and GC was estimated by calculating odds ratios (ORs) and their 95% confidence intervals (CIs) using multivariate logistic regression adjusting for sex, age and H. pylori infection status. Stratified analysis by sex and H. pylori infection status was also performed. Interactions between SNPs and the environment were investigated by including both the main effect variables and their product terms in the logistic regression models. Haplotype association analyses were performed using SHEsis online software.^30,31 A P-value < 0.05 was considered statistically significant.

Results

This study enrolled a total of 556 individuals including 208 patients with GC (GC group), 116 patients with AG (AG group) and 232 healthy control subjects (CON group).The GC group had a higher proportion of males (139 of 208; 66.8%) compared with the AG (68 of 116; 58.6%) and CON groups (136 of 232; 58.6%) but the differences were not significant (Table 1). Based on participants that had serum samples for testing, the H. pylori infection rates in the GC group (50 of 145; 34.5%) and the AG group (44 of 113; 38.9%) were significantly higher than that of the CON group (57 of 208; 27.4%) (P < 0.001).

Table 1.

Baseline demographic characteristics of patients with gastric cancer (GC group), patients with atrophic gastritis (AG) and healthy control subjects (CON group) who participated in a study of interleukin 10 gene promoter polymorphisms.

	GC group	AG group	CON group	Statistical significance^a
Characteristic	208	116	232
Age, years	58.74 ± 11.65	56.51 ± 10.74	52.27 ± 13.84	P < 0.001
Age range, years	30–84	32–79	19–84
Sex				NS
Male	139 (66.8%)	68 (58.6%)	136 (58.6%)
Female	69 (33.2%)	48 (41.4%)	96 (41.4%)
Helicobacter pylori infection^b				P < 0.001
Positive	50 (34.5%)	44 (38.9%)	57 (27.4%)
Negative	95 (65.5%)	69 (61.1%)	151 (72.6%)

Data presented as mean ± SD or n of patients (%).

^aAge was compared using analysis of variance; χ²-test was used to compare categorical variables; NS, no significant between-group difference (P ≥ 0.05).

^bParticipants with serum samples available.

The results of the association between polymorphisms (–1082A/G, –819C/T and –592A/C) of the IL10 gene promoter region and disease risk are summarized in Table 2. No significant relationship was found between the AG genotype of the IL10 gene –1082A/G polymorphism and risks of AG or GC compared with the CON group (AG: OR 1.89, 95% CI 0.90, 3.98; GC: OR 1.69, 95% CI 0.86, 3.33). The GG genotype frequency was rare in all three groups. The dominant and recessive genetic model did not demonstrate a significant result.

Table 2.

Association between interleukin 10 gene single nucleotide polymorphisms (SNP) and disease risk in patients with gastric cancer (GC group), patients with atrophic gastritis (AG) and healthy control subjects (CON group).

	Gastric mucosa status			Compared genotype	CON→AG		AG→GC		CON→GC		Non-cancer→GC
SNP	GC (%)	AG (%)	CON (%)	Compared genotype	OR (95% CI)	Statistical significance	OR (95% CI)	Statistical significance	OR (95% CI)	Statistical significance	OR (95% CI)	Statistical significance
–1082	184 (88.5)	101 (87.1)	212 (91.8)	AA	ref		ref		ref		ref
	22 (10.6)	15 (12.9)	18 (7.8)	AG	1.89 (0.90, 3.98)	NS	0.83 (0.41, 1.69)	NS	1.69 (0.86, 3.33)	NS	1.30 (0.72, 2.32)	NS
	2 (1)	0 (0)	1 (0.4)	GG	–	–	–	–	1.30 (0.11, 15.39)	NS	2.18 (0.19, 25.40)	NS
				Dominant	1.78 (0.85, 3.73)	NS	0.90 (0.45, 1.81)	NS	1.68 (0.87, 3.24)	NS	1.34 (0.76, 2.37)	NS
				Recessive	–	–	–	–	1.38 (0.12, 16.28)	NS	2.37 (0.20, 27.46)	NS
–819	85 (40.9)	41 (35.3)	92 (39.7)	TT	ref		ref		ref		ref
	100 (48.1)	47 (40.5)	104 (44.8)	CT	1.05 (0.63, 1.76)	NS	1.06 (0.63, 1.77)	NS	1.16 (0.76, 1.76)	NS	1.10 (0.76, 1.62)	NS
	23 (11.1)	28 (24.1)	36 (15.5)	CC	1.79 (0.96, 3.34)	NS	0.42 (0.21, 0.83)	P = 0.012	0.77 (0.41, 1.43)	NS	0.60 (0.34, 1.05)	NS
				Dominant	1.25 (0.78, 2.01)	NS	0.82 (0.51-1.32)	NS	1.06 (0.71, 1.57)	NS	0.95 (0.67, 1.36)	NS
				Recessive	1.79 (1.02, 3.13)	P = 0.043	0.41 (0.22, 0.75)	P = 0.004	0.71 (0.40, 1.27)	NS	0.57 (0.34, 0.96)	P = 0.034
–592	76 (36.5)	39 (33.6)	84 (36.2)	AA	ref		ref		ref		ref
	92 (44.2)	46 (39.7)	96 (41.4)	AC	1.06 (0.63, 1.79)	NS	1.04 (0.62, 1.77)	NS	1.16 (0.75, 1.79)	NS	1.10 (0.74, 1.64)	NS
	40 (19.2)	31 (26.7)	52 (22.4)	CC	1.36 (0.75, 2.48)	NS	0.68 (0.37, 1.26)	NS	0.94 (0.55, 1.62)	NS	0.84 (0.52, 1.37)	NS
				Dominant	1.18 (0.73, 1.89)	NS	0.90 (0.56, 1.46)	NS	1.09 (0.73, 1.62)	NS	1.01 (0.70, 1.46)	NS
				Recessive	1.35 (0.80, 2.27)	NS	0.66 (0.39, 1.14)	NS	0.87 (0.54, 1.40)	0.558	0.79 (0.52, 1.22)	NS

NS, no significant association (P ≥ 0.05).

For the IL10 gene –819 C/T polymorphism, the CC genotype was associated with a decreased risk in AG→GC compared with the TT genotype (OR 0.42, 95% CI 0.21, 0.83, P = 0.012) (Table 2). In the recessive genetic model, a significant decreased risk of GC was found compared with AG and non-cancer subjects, respectively (AG→GC: OR 0.41, 95% CI 0.22, 0.75, P = 0.004; non-cancer→GC: OR 0.57, 95% CI 0.34, 0.96, P = 0.034). In addition, CC genotype carriers demonstrated a significantly increased risk of AG compared with CON (OR 1.79, 95% CI 1.02, 3.13, P = 0.043).

For the IL10 gene –592A/C polymorphism, no significant association was suggested in the heterozygous, homozygous, dominant or recessive genetic models.

A subgroup investigation was undertaken to further elucidate the effect of sex and H. pylori on the results of the association analysis (Table 3). In the recessive genetic model of the IL10 gene –819C/T polymorphism, the CC genotype was significantly associated with a decreased risk of GC in males compared with AG and non-cancer, respectively (AG→GC: OR 0.35, 95% CI 0.16, 0.78, P = 0.010; non-cancer→GC: OR 0.45, 95% CI 0.23, 0.89, P = 0.022). In the subgroup analysis of H. pylori-negative participants, the CC genotype also demonstrated a significantly decreased GC risk (AG→GC: OR 0.33, 95% CI 0.14, 0.79, P = 0.013; non-cancer→GC: OR 0.41, 95% CI 0.19, 0.90, P = 0.027).

Table 3.

Subgroup analysis of the association between interleukin 10 gene –819 polymorphism and disease risk in patients with gastric cancer (GC group), patients with atrophic gastritis (AG) and healthy control subjects (CON group).

Group	GC	AG	CON	Compared genotype	CON→AG		AG→GC		CON→GC		Non-cancer→GC
Group	GC	AG	CON	Compared genotype	OR (95% CI)	Statistical significance	OR (95% CI)	Statistical significance	OR (95% CI)	Statistical significance	OR (95% CI)	Statistical significance
IL10 –819 CC versus CT+TT
All	185	88	196	CT+TT	ref		ref		ref		ref
	23	28	36	CC	1.79 (1.02, 3.13)	P = 0.043	0.41 (0.22, 0.75)	P = 0.004	0.71 (0.40, 1.27)	NS	0.57 (0.34, 0.96)	P = 0.034
Sex
Male	126	52	113	CT+TT	ref.		ref.		ref.		ref.
	13	16	23	CC	1.55 (0.75, 3.21)	NS	0.35 (0.16, 0.78)	P = 0.010	0.52 (0.25, 1.09)	NS	0.45 (0.23, 0.89)	P = 0.022
Female	59	36	83	CT+TT	ref.		ref.		ref.		ref.
	10	12	13	CC	2.20 (0.90, 5.38)	NS	0.50 (0.19, 1.28)	NS	1.20 (0.48, 3.02)	NS	0.81 (0.36, 1.84)	NS
Hp infection
Positive	42	33	50	CT+TT	ref.		ref.		ref.		ref.
	8	11	7	CC	2.69 (0.92, 7.84)	NS	0.57 (0.20, 1.59)	NS	1.70 (0.55, 5.31)	NS	0.97 (0.38, 2.46)	NS
Negative	9	17	26	CT+TT	ref.		ref.		ref.		ref.
	86	52	125	CC	1.55 (0.77, 3.14)	NS	0.33 (0.14, 0.79)	P = 0.013	0.47 (0.20, 1.10)	NS	0.41 (0.19, 0.90)	P = 0.027

Hp, Helicobacter pylori; NS, no significant association (P ≥ 0.05).

An interaction analysis was performed in order to reveal whether IL10 gene promoter polymorphisms have an interactive effect with H. pylori (Table 4). No significant interaction was observed between the IL10 gene –819 C/T polymorphism and H. pylori in CON→AG (P_interaction = 0.395), AG→GC (P_interaction = 0.387) or CON→GC (P_interaction = 0.061) under the recessive model.

Table 4.

Interaction between interleukin 10 gene –819 polymorphism and Helicobacter pylori (Hp) infection in patients with gastric cancer (GC group), patients with atrophic gastritis (AG) and healthy control subjects (CON group).

	CON→AG		AG→GC		CON→GC
Genotype	Hp positive	Hp negative	Hp positive	Hp negative	Hp positive	Hp negative
IL10 –819
CT+TT	1(ref)	1.56 (0.77, 3.16)	1(ref)	0.33 (0.14, 0.81)	1(ref)	0.48 (0.21, 1.09)
CC	1.59 (0.91, 2.79)	4.31 (1.55, 12.00)	0.75 (0.42, 1.34)	0.45 (0.17, 1.22)	1.16 (0.69, 1.95)	2.13 (0.71, 6.33)
	P_interaction = 0.395*		P_interaction = 0.387*		P_interaction = 0.061*

Data presented as odds ratio (95% confidence interval).

*No significant association (P ≥ 0.05).

Haplotype analysis was then performed to investigate the combined effect of these three promoter polymorphisms using SHEsis online software. Haplotypes with a frequency less than 1% were ignored in this software and the results are summarized in Table 5. It is suggested that ACC haplotype was associated with a significantly decreased risk of GC compared with AG (OR 0.70, 95% CI 0.50, 0.98, P = 0.038). The ATC haplotype was associated with a decreased risk of AG compared with CON (OR 0.35, 95% CI 0.13, 0.93, P = 0.028), but associated with an increased risk of GC compared with AG (OR 3.21, 95% CI 1.19, 8.65, P = 0.015). No significant relationship was detected between the other haplotypes and disease risk.

Table 5.

Haplotype analysis of the association between interleukin 10 gene –819 polymorphism and disease risk in patients with gastric cancer (GC group), patients with atrophic gastritis (AG) and healthy control subjects (CON group).

	Gastric mucosa status			CON→AG		AG→GC		CON→GC		Non-cancer→GC
Haplotype	GC	AG	CON	OR (95% CI)	Statistical significance	OR (95% CI)	Statistical significance	OR (95% CI)	Statistical significance	OR (95% CI)	Statistical significance
ATA	240.07	124.00	257.26	0.89 (0.65, 1.22)	NS	1.21 (0.88, 1.68)	NS	1.08 (0.83, 1.41)	NS	1.12 (0.88, 1.44)	NS
ACC	123.94	88.24	155.42	1.19 (0.86, 1.65)	NS	0.70 (0.50, 0.98)	P = 0.038	0.83 (0.63, 1.11)	NS	0.79 (0.60, 1.02)	NS
ATC	25.99	4.76	26.16	0.35 (0.13, 0.93)	P = 0.028	3.21 (1.19, 8.65)	P = 0.015	1.11 (0.63, 1.94)	NS	1.43 (0.84, 2.45)	NS
GCC	22.06	14.76	17.42	1.87 (0.68, 5.14)	NS	0.83 (0.42, 1.64)	NS	1.43 (0.75, 2.71)	NS	1.15 (0.66, 2.01)	NS

NS, no significant association (P ≥ 0.05).

Discussion

As an aggressive malignant tumour, GC demonstrates a high incidence and poor prognosis. Identification of reliable biomarkers associated with altered GC risk has long been a research goal to improve early detection of the disease.³² In this present study, IL10 gene –1082A/G (rs1800896), –819C/T (rs1800871) and –592A/C (rs1800872) polymorphisms were investigated in relation to the risks of GC and AG. The interaction of IL10 gene polymorphisms and H. pylori in gastric carcinogenesis was assessed and a haplotype analysis was also undertaken. The results of the recessive model (CC versus CT+TT) of the –819C/T polymorphism indicated significantly decreased risk of GC compared with AG and non-cancer subjects, respectively. In addition, the ACC haplotype was associated with a significantly decreased risk of GC compared with AG; and the ATC haplotype was associated with a decreased risk of AG compared with CON, but an increased risk of GC compared with AG. No significant interaction between IL10 promoter polymorphisms and H. pylori was found.

Cytokines have been reported to participate in the regulation of the inflammatory response of the gastric mucosa.³³ The IL10 gene is mapped to chromosome 1q31-q32, encoding a cytokine with pleiotropic effects in immunoregulation and inflammation.³⁴ For example, IL-10 inhibits the production of proinflammatory cytokines and downregulates the inflammatory response.³⁵ Genetic variants may play an important role in the pathogenesis of GC and AG.³⁶ Polymorphisms of the promoter region in the IL10 gene might influence the transcription and function of IL-10, thus altering individual susceptibility to GC. Previously, the IL10 gene (–819) polymorphism was found to be associated with an enhanced risk of peptic ulcer disease in H. pylori-positive patients.³⁷ In addition, the IL10 –819C and –592C alleles were associated with an increased risk of intestinal-type noncardia GC in H. pylori-positive subjects and current smokers.³⁸ Results from a meta-analysis found the –1082G allele significantly increased the risk of digestive cancer.³⁹ Similarly, another meta-analysis indicated that IL10 –1082 was associated with the risk of GC especially in Asian populations.⁴⁰

The present study of 208 patients with GC, 116 patients with AG and 232 healthy control subjects, found no significant relationship between IL10 –1082A/G and –592A/C polymorphisms and the risks of GC or AG in heterozygous, homozygous, dominant and recessive genetic models. A previous meta-analysis including 11 studies suggested a 13% reduced risk of GC conferred by the –819T allele compared with the –819C allele.⁴¹ This meta-analysis indicated a protective role of the T allele of the IL10 gene –819C/T polymorphism, which was in direct contrast to the results of this present research. In this present study, the CC genotype of the IL10 gene –819C/T polymorphism was associated with a decreased risk in AG→GC compared with the TT genotype. In a recessive genetic model, a significant decreased risk of GC was found compared with AG and non-cancer subjects, respectively. The different results between this current study and the meta-analysis might be due to differences between the study populations, which will require further investigations conducted in multiple ethnicities to confirm. Another meta-analysis was performed on the IL10 –592C>A polymorphism and GC.⁴² No significant association was found between the IL10 gene –592C>A polymorphism and GC risk in a total population analysis,⁴² which was in accordance with the results of this current study.

Subgroup analysis in the current study suggested that in a recessive genetic model of the IL10 gene –819C/T polymorphism, the CC genotype was significantly associated with a decreased risk of GC in males compared with AG and non-cancer, respectively. Generally, males have a higher risk of GC and relatively worse living habits compared with females, which might partly explain the detected significant association in males. As a well-known environmental pathogenic factor, chronic H. pylori infection could induce consistent inflammation.⁴³ Extensive evidence has revealed that chronic inflammation is involved in the initiation and development of GC.⁴⁴ As a result, H. pylori might be implicated in the relationship between polymorphisms of the inflammation-related gene IL10 and the occurrence of AG and GC, and might exert a degree of interaction. In the subgroup analysis of the H. pylori-negative participants in the current study, the CC genotype also demonstrated a significant decreased GC risk. Furthermore, no significant interaction was observed between the IL10 gene polymorphisms and H. pylori. These results indicated that H. pylori might not be implicated in the effect of IL10 gene polymorphisms on gastric carcinogenesis.

Interleukin-10 plays an essential role in coordinating local tissue inflammation and suppressing the immune response, thus it might exert an important effect in gastric carcinogenesis.⁴⁵ Because the IL-10-mediated inflammatory and immune environment might result in a change to the carcinogenic damage in cells, it might predispose an individual to develop GC. As a result, polymorphisms located in the promoter region of the IL10 gene might influence the binding affinity of transcriptional factors and promoter activity, thereby altering IL10 gene expression. In this current study, haplotype analysis suggested that the ACC haplotype was associated with a significantly decreased risk of GC compared with AG. The ATC haplotype was associated with a decreased risk of AG compared with the CON group, but was associated with an increased risk of GC compared with AG. Promoter polymorphisms of the IL10 gene demonstrated their combined effect in regulating gene expression and disease risk. Further large-scale study is needed to confirm the relationship between IL10 promoter polymorphisms and gastric carcinogenesis in various ethnicities.

In conclusion, the promoter –819C/T (rs1800871) polymorphism of the IL10 gene was associated with the risk of GC and AG in a Chinese population. A consistent relationship was also found in males and H. pylori-negative subgroups. No significant interaction was detected between IL10 promoter polymorphisms and H. pylori. In haplotype analysis, the ACC haplotype was associated with a significantly decreased risk of GC compared with AG. The ATC haplotype was associated with a decreased risk of AG compared with the healthy controls, but was associated with an increased risk of GC compared with AG.

Footnotes

Declaration of conflicting interests

The authors declare that there are no conflicts of interest.

Funding

This study is supported by grants from The National Basic Research Programme of China (973 Program ref. 2010CB529304) and The National Science and Technology Support Programme (no. 2015BAI13B07).

References

Siegel

Ward

Brawley

et al . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212–236.

Chia

Tan

Molecular classification of gastric cancer.

Ann Oncol 2016; 27: 763–769.

Zabaleta

Multifactorial etiology of gastric cancer.

Methods Mol Biol 2012; 863: 411–435.

Saeki

Ono

Sakamoto

et al . Genetic factors related to gastric cancer susceptibility identified using a genome-wide association study. Cancer Sci 2013; 104: 1–8.

Lee

Hwang

Nam

KT.

Immune response and the tumor microenvironment: how they communicate to regulate gastric cancer.

Gut Liver 2014; 8: 131–139.

Stanley

Lacy

Pathways for cytokine secretion.

Physiology (Bethesda) 2010; 25: 218–229.

Mosser

Zhang

Interleukin-10: new perspectives on an old cytokine.

Immunol Rev 2008; 226: 205–218.

Howell

Rose-Zerilli

MJ.

Interleukin-10 polymorphisms, cancer susceptibility and prognosis.

Fam Cancer 2006; 5: 143–149.

Mannino

Zhu

Xiao

et al . The paradoxical role of IL-10 in immunity and cancer. Cancer Lett 2015; 367: 103–107.

10.

Walos

Szary

Szala

Inhibition of tumor growth by interleukin 10 gene transfer in B16(F10) melanoma cells.

Acta Biochim Pol 1999; 46: 967–970.

11.

Correa

Human gastric carcinogenesis: a multistep and multifactorial process – First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735–6740.

12.

Hartgrink

Jansen

van Grieken

et al . Gastric cancer. Lancet 2009; 374: 477–490.

13.

Chen

Liu

et al . Host genetic factors respond to pathogenic step-specific virulence factors of Helicobacter pylori in gastric carcinogenesis. Mutat Res Rev Mutat Res 2014; 759: 14–26.

14.

Achyut

Ghoshal

Moorchung

et al . Role of cyclooxygenase-2 functional gene polymorphisms in Helicobacter pylori induced gastritis and gastric atrophy. Mol Cell Biochem 2009; 321: 103–109.

15.

Ohyauchi

Imatani

Yonechi

et al . The polymorphism interleukin 8 –251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. Gut 2005; 54: 330–335.

16.

Pan

Zhang

et al . Genetic polymorphisms of interleukin (IL)-1B, IL-1RN, IL-8, IL-10 and tumor necrosis factor {alpha} and risk of gastric cancer in a Chinese population. Carcinogenesis 2005; 26: 631–636.

17.

Sun

et al . Helicobacter pylori-related host gene polymorphisms associated with susceptibility of gastric carcinogenesis: a two-stage case-control study in Chinese. Carcinogenesis 2013; 34: 1450–1457.

18.

et al . Polymorphic rs9471643 and rs6458238 upregulate PGC transcription and protein expression in overdominant or dominant models. Mol Carcinog 2016; 55: 586–599.

19.

Sun

Dong

et al . Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study. Int J Cancer 2015; 136: 425–434.

20.

Stolte

Meining

The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol 2001; 15: 591–598.

21.

Dixon

Genta

Yardley

et al . Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161–1181.

22.

Hamilton

Aaltonen

(eds). Pathology and genetics of tumours of the digestive system. World Health Organization. International Agency for Research on Cancer. Oxford: IARC Press, 2000, pp.237–240.

23.

Roh

Kim

Seo

et al . Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett 2002; 184: 57–63.

24.

Shih

Lee

Chiou

et al . The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 2005; 50: 291–297.

25.

Yao

Gao

Liu

et al . Genetic variation in interleukin-10 gene and risk of oral cancer. Clin Chim Acta 2008; 388: 84–88.

26.

Zhang

Chen

et al . Correlation between polymorphism of IL-4 and IL-10 gene promoter and childhood asthma and their impact upon cytokine expression. Zhonghua Yi Xue Za Zhi 2002; 82: 114–118 [in Chinese, English Abstract].

27.

Brisson-Noel

Aznar

Chureau

et al . Diagnosis of tuberculosis by DNA amplification in clinical practice evaluation. Lancet 1991; 338: 364–366.

28.

Brisson-Noël

Gicquel

Lecossier

et al . Rapid diagnosis of tuberculosis by amplification of mycobacterial DNA in clinical samples. Lancet 1989; 2: 1069–1071.

29.

Gong

Sun

Jin

et al . Comparative study of serology and histology based detection of Helicobacter pylori infections: a large population-based study of 7,241 subjects from China. Eur J Clin Microbiol Infect Dis 2010; 29: 907–911.

30.

Shi

SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci.

Cell Res 2005; 15: 97–98.

31.

Zhang

et al . A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res 2009; 19: 519–523.

32.

Suh

Yang

HK.

Screening and early detection of gastric cancer: east versus west.

Surg Clin North Am 2015; 95: 1053–1066.

33.

Lundin

Enarsson

Kindlund

et al . The local and systemic T-cell response to Helicobacter pylori in gastric cancer patients is characterised by production of interleukin-10. Clin Immunol 2007; 125: 205–213.

34.

Abdalla

Lambert

Duan

et al . Interleukin-10 family and tuberculosis: an old story renewed. Int J Biol Sci 2016; 12: 710–717.

35.

Geginat

Larghi

Paroni

et al . The light and the dark sides of interleukin-10 in immune-mediated diseases and cancer. Cytokine Growth Factor Rev 2016; 30: 87–93.

36.

Gigek

Calcagno

Rasmussen

et al . Genetic variants in gastric cancer: risks and clinical implications. Exp Mol Pathol 2017; 103: 101–111.

37.

Ramis

Vianna

Goncalves

et al . Polymorphisms of the IL-6, IL-8 and IL-10 genes and the risk of gastric pathology in patients infected with Helicobacter pylori. J Microbiol Immunol Infect 2017; 50: 153–159.

38.

Kim

Cho

Choi

et al . Effects of interleukin-10 polymorphisms, helicobacter pylori infection, and smoking on the risk of noncardia gastric cancer. PloS One 2012; 7: e29643.

39.

Tong

Liu

et al . The -1082A>G polymorphism in promoter region of interleukin-10 and risk of digestive cancer: a meta-analysis. Sci Rep 2014; 4: 5335.

40.

Xue

et al . A meta-analysis of interleukin-10-1082 promoter polymorphism associated with gastric cancer risk. DNA Cell Biol 2012; 31: 582–591.

41.

Cui

Huang

et al . Relationship between interleukin-10 gene C-819T polymorphism and gastric cancer risk: insights from a meta-analysis. Med Sci Monit 2016; 22: 2839–2845.

42.

Liu

Pan

et al . Interleukin-10 gene -592C>a polymorphism and susceptibility to gastric cancer. Genet Mol Res 2014; 13: 8954–8961.

43.

Burucoa

Axon

Epidemiology of helicobacter pylori infection. Helicobacter 2017; 22(Suppl 1). doi: 10.1111/hel.12403.

44.

Wang

Meng

Wang

et al . Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett 2014; 345: 196–202.

45.

Kole

Maloy

KJ.

Control of intestinal inflammation by interleukin-10.

Curr Top Microbiol Immunol 2014; 380: 19–38.

Association of IL10 gene promoter polymorphisms with risks of gastric cancer and atrophic gastritis

Abstract

Objective

Methods

Results

Conclusion

Keywords

Introduction

Patients and methods

Study population

Genotyping of IL10 gene –1082A/G, –819C/T and –592A/C polymorphisms

Helicobacter pylori infection status

Statistical analyses

Results

Discussion

Footnotes

Declaration of conflicting interests

Funding

References